Celularity Inc. (CELU)
NASDAQ: CELU · Real-Time Price · USD
2.040
+0.590 (40.55%)
Nov 7, 2024, 11:30 AM EST - Market open

Company Description

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases.

The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn’s disease.

In addition, the company is developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis.

Celularity Inc. produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand.

The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates.

Celularity Inc. was founded in 1998 and is based in Florham Park, New Jersey.

Celularity Inc.
Celularity logo
Country United States
Founded 2016
Industry Biotechnology
Sector Healthcare
Employees 120
CEO Robert Hariri

Contact Details

Address:
170 Park Avenue
Florham Park, New Jersey 07932
United States
Phone 908 768 2170
Website celularity.com

Stock Details

Ticker Symbol CELU
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001752828
CUSIP Number 151190105
ISIN Number US1511902041
Employer ID 83-1702591
SIC Code 2834

Key Executives

Name Position
Dr. Robert Joseph Hariri M.D., Ph.D. Founder, Chief Executive Officer and Chairman
John R. Haines Senior EVice President, Global Manager and Chief Administrative Officer
David C. Beers C.F.A. Chief Financial Officer
Carlos Ramirez SVice President of Investor Relations
Kyle Harold Fletcher Esq. Executive Vice President, General Counsel and Chief Compliance Officer
Dr. Stephen A. Brigido D.P.M. President of Degenerative Diseases
Sharmila Koppisetti M.D. Senior Vice President of Clinical Dev. Immunology and Drug Safety
Tim Wilk Senior Vice President of Technical Operations
David Jakob Lemus CPA, M.S., MBA Treasurer
Timothy Smith Secretary

Latest SEC Filings

Date Type Title
Nov 7, 2024 8-K Current Report
Nov 7, 2024 10-Q Quarterly Report
Oct 25, 2024 8-K Current Report
Oct 21, 2024 8-K Current Report
Oct 16, 2024 10-Q Quarterly Report
Oct 16, 2024 8-K Current Report
Sep 13, 2024 8-K Current Report
Aug 28, 2024 8-K Current Report
Aug 23, 2024 8-K Current Report
Aug 16, 2024 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB